Drug Resistance Immunotherapy for Cancer Treatment Using a Chimeric Antigen Receptor Approach Open Access
Tylawsky, Daniel Eugene (2015)
Published
Abstract
The toxicity of nucleoside analogue chemotherapeutics on rapidly proliferating cells is a well documented and understood side effect of cancer treatment. One of the most consequential trade-offs of this off-tumor cytotoxicity is that it acts on immune system cells that have a natural capacity to fight tumors. As such, making immunocompetent cells resistant to a chemotherapeutic, so that they can stay alive during it's administration, is a desirable approach to enhance cancer treatment with chemotherapy. This is the basis for drug resistant immunotherapy (DRI), which we implement in our studies. We think that by combining novel immunotherapy strategies with currently used chemotherapy protocols, a potent and enduring cancer treatment can be achieved. In this study, we investigated the ability of overexpressed cytidine deaminase to confer resistance to the chemotherapeutic Ara-C and showed that this could be achieved in MV4-11 cells. For the immunotherapy arm of our studies, we experimented with engineering a chimeric antigen receptor (CAR) to enhance the specificity and activation of immunocompetent cells. We took a novel approach in constructing a CAR by utilizing a variable lymphocyte receptor (VLR) derived from lampreys, to function as the specific antigen-binding portion of the construct. This was done because the independently evolved adaptive immune system of jawless fish, which utilizes VLRs, can potentially recognize epitopes distinct from those recognized by mammalian antibodies. In this study, we experimented with an anti-CD5 VLR-CAR construct. We observed that Jurkat cells transduced with anti-CD5 VLR-CAR encoded lentivirus, were in fact successfully activated in the presence of CD5+ Jurkat cells. This proved that not only can VLRs be effectively used in a CAR construct, but also, for the first time, can activate T cells against a therapeutically relevant antigen.
Table of Contents
Introduction 1
Methods 9
Results 15
Discussion 21
References 27
Tables and Figures
Table 1 31
Table 2 37
Figure 1 29
Figure 2 30
Figure 3 31
Figure 4 32
Figure 5 33
Figure 6 34
Figure 7 35
Figure 8 36
Figure 9 37
Figure 10 39
Figure 11 40
Figure 12 41
Figure 13 42
Figure 14 43
Figure 15 44
About this Honors Thesis
| School | |
|---|---|
| Department | |
| Degree | |
| Submission | |
| Language |
|
| Research Field | |
| Keyword | |
| Committee Chair / Thesis Advisor | |
| Committee Members |
Primary PDF
| Thumbnail | Title | Date Uploaded | Actions |
|---|---|---|---|
|
|
Drug Resistance Immunotherapy for Cancer Treatment Using a Chimeric Antigen Receptor Approach () | 2018-08-28 12:28:25 -0400 |
|
Supplemental Files
| Thumbnail | Title | Date Uploaded | Actions |
|---|